Status:
TERMINATED
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
Lead Sponsor:
Wenhu Liu
Conditions:
Idiopathic Membranous Nephropathy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Multi-center, prospective, randomized, controlled study to verify the efficacy of prednisone alone and combination therapy with methylprednisolone and cyclophosphamide in the treatment of stage I memb...
Detailed Description
Idiopathic membranous nephropathy (IMN) is one of the most common cause of adult nephrotic syndrome. Prednisolone and methylprednisolone are essential drugs for IMN. However, there are no recommendati...
Eligibility Criteria
Inclusion
- The pathological examination of renal biopsy was consistent with the early idiopathic membranous nephropathy
- Meeting one of the following three condition：
- Urine protein quantitation \>4g/d,or 50% higher than baseline,RASS blocker treat for 6 months without trend of decrease ②Serious or disabling complications related to nephrotic syndrome ③In the 6-12 months after diagnosis of idiopathic membranous nephropathy, serum creatinine increased by more than 30%, while eGFR eGFR≥25ml/min/1.73m2.And excludeing other causes of renal dysfunction
Exclusion
- Secondary membranous nephropathy
- Serious complications
- Considering the effect of cyclophosphamide on the of function of sex gland，all patients with childbearing age or fertility requirement cannot participate in this study
Key Trial Info
Start Date :
March 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03466801
Start Date
March 20 2018
End Date
June 30 2019
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital, Capital Medical University
Beijing, China, 100050